학술논문
Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study
Document Type
Article
Author
Source
In The Lancet Oncology July 2023 24(7):744-756
Subject
Language
ISSN
1470-2045